Vaccination

Interleukin-2 Fusion Protein Enhances DNA Vaccine Effectiveness

Published in Gene Therapy Weekly, October 18th, 2001

by Sonia Nichols, senior medical writer - Researchers at Scripps Clinic and Research Institute in California have used a cytokine fusion protein to heighten the effectiveness of oral DNA vaccine against murine tumors.

Combination therapy, in effect, makes a good vaccine better. A.G. Niethammer and colleagues used a mouse-human antiganglioside GD2-interleukin (IL)-2 fusion protein (ch14, 18-IL2) to show that targeting IL-2 at the tumor microenvironment boosted immune response against murine melanoma when mice were administered oral DNA vaccines produced by fusing murine ubiquitin genes with murine melanoma peptide epitopes. Attenuated Salmonella typhimurium was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry